MoonLake Immunotherapeutics
MLTX13.830USD
-0.040-0.29%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
881.03MMarket Cap
LossP/E TTM
MoonLake Immunotherapeutics Earnings Date
Period
FY2024 Earnings Date
Revenue(YoY)
--
--
EPS(YoY)
-1.89
-158.08%
Analyst Rating
BUY
2025-12-09
Financial Indicators
EPS
Revenue
Net Profit
Net Margin
Gross Margin
Debt to assets ratio
ROE
ROA
Relevant data have not been disclosed by the company yet.
Income Statement
Revenue
Operating profit
Net Profit
Relevant data have not been disclosed by the company yet.
Balance Sheet
Current assets
Total current liabilities
Total assets
Total liabilities
Total equity
Relevant data have not been disclosed by the company yet.
Cash Flow Statement
Net operating income
Net investment
Net financing
Relevant data have not been disclosed by the company yet.
FAQs
What is the total revenue of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its total revenue reached --, with a year-on-year change of --.
What is the Earnings Per Share (EPS) of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its Earnings Per Share (EPS) was -1.892, with a year-on-year change of -158.08%.
What is the net income of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its net income was -118.94M, with a year-on-year change of -230.31%.
What is the net margin of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its net profit margin was --, with a year-on-year change of --.
What is the gross margin of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its gross margin was --, with a year-on-year change of --.
What is the debt-to-asset ratio of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its debt-to-asset ratio was --, with a year-on-year change of --.
What is the Return on Equity (ROE) of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its Return on Equity (ROE) was -25.24%, with a year-on-year change of -90.85%.
What is the Return on Assets (ROA) of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its Return on Assets (ROA) was -24.14%, with a year-on-year change of -65.23%.
What is the operating profit of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its operating profit was -143.09M, with a year-on-year change of -164.38%.
What are the current assets of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its current assets were 474.29M, with a year-on-year change of -7.76%.
What are the total assets of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its total assets of MoonLake Immunotherapeutics were 477.93M, with a year-on-year change of -9.23%.
What are the total liabilities of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its total liabilities of MoonLake Immunotherapeutics were 24.54M, with a year-on-year change of 88.08%.
What is the total equity of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its total equity of MoonLake Immunotherapeutics was 453.39M, with a year-on-year change of -11.70%.
What is the net operating income of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its net operating income of MoonLake Immunotherapeutics was -121.24M, with a year-on-year change of -175.06%.
What is the net investment of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its net investment of MoonLake Immunotherapeutics was -205.60M, with a year-on-year change of -716.36%.
What is the net financing of MoonLake Immunotherapeutics?
According to MoonLake Immunotherapeutics's FY2024 earnings report, its net financing of MoonLake Immunotherapeutics was 51.31M, with a year-on-year change of -89.30%.
